Abbott's FreeStyle ® Libre 14 Day System Now Available in U.S. for Hospitalized Patients with Diabetes During COVID-19 Pandemic
-- More than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized, according to a report from the Centers for Disease Control and Prevention (CDC) ¹ (Source: Abbott.com)
Source: Abbott.com - April 8, 2020 Category: Pharmaceuticals Source Type: news
Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes
- The Abbott ID NOW ™ COVID-19 test brings rapid testing to the front lines (Source: Abbott.com)
Source: Abbott.com - March 27, 2020 Category: Pharmaceuticals Source Type: news
Abbott Hosts Conference Call for First-Quarter Earnings
(Source: Abbott.com)
Source: Abbott.com - March 19, 2020 Category: Pharmaceuticals Source Type: news
Abbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus
- The test will be used on the company's m2000 RealTime system that is currently available in hospitals and molecular laboratories in the U.S. (Source: Abbott.com)
Source: Abbott.com - March 18, 2020 Category: Pharmaceuticals Source Type: news
Abbott Aims to Optimize TAVI Implants with European Approval of FlexNav ™ Delivery System for the Company's Portico™ Valve
- New FlexNav ™ delivery system improves control and delivery of the Portico™ TAVI valve even in complex clinical cases (Source: Abbott.com)
Source: Abbott.com - March 5, 2020 Category: Pharmaceuticals Source Type: news
Abbott Declares 385th Consecutive Quarterly Dividend
(Source: Abbott.com)
Source: Abbott.com - February 21, 2020 Category: Pharmaceuticals Source Type: news
New Real-World Data Show that Abbott's FreeStyle Libre System Delivers Positive Health Outcomes for People with Type 1 and Type 2 Diabetes
- Data at ATTD reinforce and add to a growing body of clinical research and real-world evidence from users of the FreeStyle Libre system around the world (Source: Abbott.com)
Source: Abbott.com - February 20, 2020 Category: Pharmaceuticals Source Type: news
Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care
- Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon ™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform (Source: Abbott.com)
Source: Abbott.com - February 19, 2020 Category: Pharmaceuticals Source Type: news
Abbott Introduces Next-Generation Heart Rhythm Management Devices in Europe, Featuring State-of-the-Art Patient App and Bluetooth Connectivity
- New Gallant ™ high voltage devices offer patients and their doctors a smartphone app and Bluetooth connectivity designed to help doctors tailor therapy to a patient's unique clinical needs (Source: Abbott.com)
Source: Abbott.com - February 18, 2020 Category: Pharmaceuticals Source Type: news
Abbott's In-Development Fully Implantable Heart Pump System Earns FDA's Breakthrough Device Designation
(Source: Abbott.com)
Source: Abbott.com - February 4, 2020 Category: Pharmaceuticals Source Type: news
Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke
- The CATALYST trial will examine Abbott's Amplatzer ™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation (Source: Abbott.com)
Source: Abbott.com - February 3, 2020 Category: Pharmaceuticals Source Type: news
Abbott's Tendyne ™ Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation
- First-of-its-kind technology addresses critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option (Source: Abbott.com)
Source: Abbott.com - January 30, 2020 Category: Pharmaceuticals Source Type: news
Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson's Disease
- Abbott's Infinity ™ DBS is the first FDA approved directional Deep Brain Stimulation (DBS) system to allow targeting of a specific area of the brain that is critical to motor functions (Source: Abbott.com)
Source: Abbott.com - January 24, 2020 Category: Pharmaceuticals Source Type: news
New Quality of Life and Functional Improvement Data From Abbott's BOLD and TRIUMPH Studies Reinforce Benefit of Proclaim ™ XR Neurostimulation System In People Living with Chronic Pain
- BOLD study found that BurstDR ™ stimulation waveform reduced the negative psychological effects associated with a person's chronic pain at six-month follow up by 62% (Source: Abbott.com)
Source: Abbott.com - January 23, 2020 Category: Pharmaceuticals Source Type: news
Abbott Reports Fourth-Quarter 2019 Results; Announces Strong Forecast for 2020
- Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent (Source: Abbott.com)
Source: Abbott.com - January 22, 2020 Category: Pharmaceuticals Source Type: news
